Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-03), Venus Medtech (Hangzhou)'s 12-1 Month Momentum % is 67.95%.
The industry rank for Venus Medtech (Hangzhou)'s 12-1 Month Momentum % or its related term are showing as below:
VMTHF's 12-1 Month Momentum % is ranked worse than 90.8% of 826
companies
in the Medical Devices & Instruments industry
Industry Median: -18.27
vs VMTHF: 67.95
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Venus Medtech (Hangzhou) 12-1 Month Momentum % Related Terms
VMTHF vs ABT, SYK, MDT: 12-1 Month Momentum % Comparison
For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venus Medtech (Hangzhou) 12-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Venus Medtech (Hangzhou)'s 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venus Medtech (Hangzhou) (VMTHF) has a 12-1 Month Momentum % of 67.95% as of Aug. 03, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Venus Medtech (Hangzhou) and its competitors. According to the industry distribution chart, Venus Medtech (Hangzhou) ranks #750 out of 826 companies in the Medical Devices & Instruments industry, placing it in the top 90.8%.
Is Venus Medtech (Hangzhou)'s 12-1 Month Momentum % too high?
Venus Medtech (Hangzhou)'s current 12-1 Month Momentum % is 67.95%. Based on the distribution chart, Venus Medtech (Hangzhou) ranks #750 out of 826 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Venus Medtech (Hangzhou) has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Venus Medtech (Hangzhou)'s 12-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Venus Medtech (Hangzhou) ranks #750 out of 826 companies for 12-1 Month Momentum %. This places Venus Medtech (Hangzhou) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Devices & Instruments company?
A good 12-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Venus Medtech (Hangzhou) and its competitors. Venus Medtech (Hangzhou)'s current 12-1 Month Momentum % is 67.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venus Medtech (Hangzhou) stock overvalued right now?
Venus Medtech (Hangzhou) (VMTHF) has a current 12-1 Month Momentum % of 67.95%. The stock's GF Value™ is $1.27, compared to a current price of $0.42 — trading 66.8% below its estimated fair value. The current 12-1 Month Momentum % is 67.95%. Venus Medtech (Hangzhou)'s overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Venus Medtech (Hangzhou) (VMTHF), the current 12-1 Month Momentum % is 67.95% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Venus Medtech (Hangzhou) (VMTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Venus Medtech (Hangzhou) stock appears to be undervalued.
The current stock price of $0.42 is trading 66.8% below its estimated GF Value™ of $1.27.
Key valuation signals for VMTHF:
12-1 Month Momentum %: 67.95%
GF Value™: $1.27 vs. price of $0.42 (66.8% below fair value)
No single metric tells the full story. See the VMTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Venus Medtech (Hangzhou) Inc is engaged in the medical devices that integrate R&D, clinical development, manufacturing, and commercialization. The company has developed a product portfolio covering the interventional devices for valvular heart diseases, including transcatheter aortic valve replacement (TAVR), transcatheter pulmonary valve replacement (TPVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), and other procedural accessories, allowing it to provide overall solutions for physicians and patients. Geographically, the company operates in mainland China, Israel, Hong Kong, the USA, and the Netherlands. The majority of the revenue is derived from Mainland China.
52GF Score
Get the complete analysis for VMTHF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMTHF has been successfully added to your 
